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Our objective is to investigate the relationship between drug and menstrual cycle symptoms in HIV+ women receiving antiretro-
viral therapy (HAART). Interviews were done for 12 weeks with 54 HIV+ women receiving HAART. Patients were asked if they
experienced any of 28 symptoms associated with HAART and the menstrual cycle and about HAART adherence. Weeks were di-
vided into menstrual weeks (MWs), premenstrual weeks (PWs), and other weeks. Women reported more bloating (P = .02) and
cramps (P = .001) during MWs. Skin problems (P = .08) and breast tenderness (P = .03) were experienced during PWs. Feeling
tired/loss of energy (P = .05), joint pain (P = .02), and chills (P = .03) were higher in non-MW/PWs. Women were slightly
less adherent during the MWs (89%) than PWs (94%) and other weeks (93%). Feeling sad or depressed (P = .01) was associated
with nonadherence. Experiencing certain symptoms associated with both the menstrual cycle and HAART drugs was related with
nonadherence.
Copyright © 2006 P. N. Patel and R. M. Grimes. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
INTRODUCTION
Use of multidrug antiretroviral therapy to suppress viral rep-
lication is the recommended approach to treatment of HIV
infected patients who meet certain clinical criteria. This has
been demonstrated to reduce HIV-related morbidity and
mortality. The current treatment guidelines suggest that pa-
tients be treated with highly active antiretroviral therapy
(HAART), utilizing 3-4 drugs of at least two diﬀerent classes
[1, 2].
However, this treatment requires strict adherence in or-
der to successfully suppress the virus. Paterson showed that
taking over 95% of the doses was necessary to maximally
suppress viral replication [3]. Failure to suppress the viral
load to very low levels has been associated with the devel-
opment of drug resistant virus. However, antiretroviral reg-
imens are diﬃcult to follow on a daily basis due to meal re-
strictions, complex dosing schedules, and side eﬀects. Many
studies have been conducted to try to develop predictors of
adherence and nonadherence to antiretroviral regimens.
Factors associated with adherence include availability of
social support systems, patients being able to ﬁt their medi-
cationsintotheirdailyroutine,andthepatient’sunderstand-
ing that poor adherence leads to resistance. Other factors in-
clude understanding the importance of taking all medication
doses, feeling comfortable taking medications in front of
other people, having signiﬁcant others who are knowledge-
able and agree with the treatment regimen as well as keeping
scheduled clinic appointments [2–4].
Factors that contribute to poor adherence include com-
plex treatment regimens, large numbers of pills or high fre-
quency of dosing, a poor doctor-patient relationship, sub-
stance use, depression, and patient beliefs as well as food
restrictions [5]. Moreover, main reasons for missing doses
include forgetting, being too busy, being depressed, and hav-
ing severe drug-related side eﬀects [2]. The list of side eﬀects
from patients taking HAART include rash, dryness or itch-
ing, fatigue/loss of energy, diﬃculty falling or staying asleep,
pain and numbness in the hands and feet, diarrhea, nausea
and vomiting, trouble remembering, and changes in the way
a patient’s body may look due to weight gain or fat deposits
[6]. Other side eﬀects include anxiety, confusion, and vision
problems [7].
Ithasalsobeennotedthatwomenarelessadherenttoan-
tiretroviral regimens when compared to men [8, 9]. Previous
reports have linked women being unable to adhere to their
regimen to the fact that women are more likely than men to
mentionneedingtocareforothersasafactorcontributingto
their busy schedules [10]. Gender diﬀerences have also been
attributedtohormonaleﬀectsontheimmunesystem[7–11].2 Infectious Diseases in Obstetrics and Gynecology
Given that there is evidence that adherence is poorer in
women and that side eﬀects have been shown to aﬀect the
rate of adherence, it is necessary to examine factors that are
unique to women that might impact side eﬀects. The most
obvious diﬀerences are biological. Among these are men-
struation and the menstrual cycle. It is known that there
can be a variety of symptoms at various times during the
menstrual cycle. These symptoms include pain, water re-
tention, negative aﬀect, impaired concentration, behavioral
change, arousal, and irritability. Other symptoms include
anger, being anxious, crying, depression, diﬃculty sleep-
ing or sleeping too much, mood swings, being stressed out,
overwhelmed, sensitivity, sudden sadness, appetite changes,
backlashes, bloating, breast tenderness, cramping, head-
aches,tired/lackofenergy,andweightgain[12,13].Itshould
be noted that many of these symptoms overlap with the side
eﬀects of antiretroviral therapy and could be associated with
forgetting to take or electing not to take one’s medications.
Therefore, it seemed reasonable to examine whether ad-
herence ﬂuctuates throughout the menstrual cycle, whether
HAART-related symptoms are experienced more frequently
during various times in the cycle, and whether the symptoms
aﬀectadherence.Anextensive reviewoftheliteraturedidnot
reveal any studies that have tested whether a woman’s phase
of the menstrual cycle intensiﬁes the symptoms associated
with HAART.
SUBJECTS AND METHODS
Patients were recruited from three diﬀerent clinics in Hous-
ton, Texas, USA, which are conducted by the Harris County
Hospital District. These clinics only see indigent patients or
those who are eligible for Medicaid. Women who were HIV
positive, currently experiencing menstrual cycles, currently
taking HAART, able to speak English and had a telephone
were eligible for inclusion in the study. If the patient met the
inclusion criteria and was interested in participation, she was
then given an informed consent document to read and sign.
A drug recall questionnaire and the signs and symptoms
checklist questionnaire (see Table 1) were given to the pa-
tients after they gave consent to participate in the study.
These questionnaires asked the women to specify their ad-
herencetotheirHAARTregimensandwhichsymptomsthey
experienced during the week prior to the beginning of the
study. An additional question was asked to determine if the
woman had had a menstrual period in the previous week.
Basic demographic information was collected at this time.
Thereafter, telephone interviews asking the symptom,
drug recall and menstrual period questions were conducted
every week for up to twelve weeks. If patients were unable
to be contacted on the day of followup, attempts to contact
were made on the subsequent two days. If the patient was
unable to be reached by the third day the patient’s response
for that given week was recorded as a nonresponse for that
week. If patients were not able to be contacted between their
last contact and the end of the twelve-week period, they were
considered lost to follow up and their data were truncated at
that point.
The drug recall questionnaire was also administered
weekly for each antiretroviral drug the patient was currently
taking, in order to determine which medications the patient
missed as well as to quantify the number of doses missed for
each drug. Once patients identiﬁed that they had started a
periodduringthepreviousweek,thatweekwasdesignatedas
a “menstrual week” (MW). The week prior to that was des-
ignated as the “premenstrual week” (PW). All other weeks
since the last period were designated as “nonmenstrual or
premenstrual weeks” (non-MW/PWs).
Data were maintained in a SPSS 11.0 database and were
analyzed using X2 test and Fisher’s exact test for variables
tested.
RESULTS
A total of 54 patients who met the inclusion criteria were en-
rolled in the study. Thirteen possible weeks of information
were collected (baseline and 12 phone calls); so there was a
potential of collecting 702 weeks of menstrual cycle experi-
ence and drug adherence information. Fifteen patients were
lost to followup sometime during the study and partial data
were collected for these patients since inclusion criteria were
still met. Two patients stopped taking HAART during the
study. Data from the weeks prior to their stopping were used
in the analysis. This reduced the number of possible weeks
for which data could be collected to 525 weeks. Patients were
able to be contacted during 380 or 72.4% of those weeks.
Data were collected for 87 menstrual weeks, 67 premenstrual
weeks, and 226 other weeks.
The sample consisted of 41 African-Americans (75.9%),
10 Hispanics (18.5%), and 3 Anglo (5.5 % )w o m e n .T h e
mean age was 36.9y e a r s .Table 1 shows the distribution
of symptoms by cycle phase during the three-month pe-
riod among 54 patients enrolled in the study. It presents
each symptom’s occurrence in relation to each of the three
cycle phases. Signiﬁcant values (P<. 05) were identiﬁed
for 6 out of the 28 symptoms and mildly signiﬁcant val-
ues (>. 05 <. 10) were identiﬁed for 2 of the 28 symptoms.
As would be expected, women were more likely to expe-
rience feeling bloated (P = .02) and cramps (P = .001)
during the menstrual week. Taste perversions seemed to be
less likely to occur during the menstrual week (P = .08).
Breast tenderness was more likely to occur during both the
menstrual and premenstrual weeks (P = .03). Women were
marginally more likely to report skin problems during the
premenstrual week (P = .07). It was interesting that three of
the symptoms—tiredness (P = .05), joint pain (P = .02),
and experiencing chills (P = .03) were more likely to occur
during non-MW/PWs.
The next portion of the analysis examined the relation-
ship between drug adherence and cycle phase. Patients were
queried as to whether they had missed any doses during that
week. If the patient missed any doses they were deemed to
be nonadherent for that week. This rather stringent criterion
was utilized because Paterson had shown that adherence at
less than 95% was associated with treatment failure [3]. All
of the study subjects were taking dosages that required 2-3P. N. Patel and R. M. Grimes 3
Table 1: Frequency of symptoms by cycle phase among 54 study patients. NS= not signiﬁcant.
Symptom Menstrual week Premenstrual week Other weeks Signiﬁcance
N = 87(%) N = 67(%) N = 226(%)
Skin problems 17 (19.5) 24 (38.5) 63 (27.9) P = .07
Feeling tired or loss of energy 42 (48.3) 38 (56.7) 143 (63.3) P = .05
Diﬃculty falling asleep 42 (48.3) 33 (49.3) 111 (49.1) NS
Diﬃculty staying asleep 37 (42.5) 34 (50.7) 103 (45.6) NS
Pain/numbness in hands and feet 33 (37.9) 30 (44.8) 97 (42.9) NS
Feeling like throwing up 25 (28.7) 22 (32.8) 74 (32.7) NS
Vomiting 7 (8.0) 6 (9.0) 33 (14.6) NS
Trouble remembering 44 (50.6) 30 (44.8) 106 (46.9) NS
Pain in joints 30 (34.5) 24 (35.8) 112 (49.6) P = .02
Pain in stomach 25 (28.7) 17 (25.4) 61 (27.0) NS
Felt sad or depressed 31 (35.6) 25 (37.3) 92 (40.7) NS
Muscle aches 41 (47.1) 28 (41.8) 117 (51.8) NS
Felt nervous or anxious 30 (34.5) 27 (40.3) 84 (37.2) NS
Diarrhea or loose bowel movement 23 (26.4) 19 (28.4) 60 (26.5) NS
Headaches 47 (54.0) 29 (43.3) 129 (57.1) NS
Hair loss or changes in way hair looks 18 (20.7) 15 (22.4) 43 (19.0) NS
Problems with weight loss 8 (9.2) 10 (14.9) 38 (16.8) NS
Problems with weight gain 20 (23.0) 20 (29.9) 61 (27.0) NS
Problems with having sex 15 (17.2) 17 (25.4) 43 (19.0) NS
Feeling dizzy or lightheaded 32 (36.8) 25 (37.3) 91 (40.3) NS
Feeling bloated 46 (52.9) 28 (41.8) 79 (35.0) P = .02
Fever 17 (19.5) 11 (16.4) 49 (21.7) NS
Noticing that food tastes funny 13 (14.9) 16 (23.9) 61 (27.0) P = .08
Swelling or tenderness in breasts 30 (34.5) 24 (35.8) 51 (22.6) P = .03
Loss of appetite 19 (21.8) 13 (19.4) 55 (24.3) NS
Chills 16 (18.4) 17 (20.9) 72 (31.9) P = .03
Unusual sweating 26 (29.9) 22 (32.8) 72 (31.9) NS
Cramps 48 (55.2) 20 (29.9) 77 (34.1) P = .001
administrations per day. Therefore, missing a single dose in
a week meant that the patient’s adherence was less than 95%.
A chi-square analysis was conducted for this relationship. It
was noted that women were less adherent during the men-
strualweek(89%)thanduringthepremenstrualweek(94%)
and non-MW/PWs (93%). However, this diﬀerence was not
statistically signiﬁcant (see Table 2).
The ﬁnal analysis examined the relationship between the
listofsymptomsinTable 1 andadherencetotheHAARTreg-
imen. Only one of the symptoms was signiﬁcant at the 0.05
level.Feelingsadordepressedwasassociatedwithnonadher-
ence (P = .01).
DISCUSSION
The data collected from this study shows that some of
the symptoms that are associated with HAART seem to be
exacerbated during a woman’s menstrual cycle. What was
surprising was the degree to which these symptoms were re-
ported by these women. Of the 28 symptoms in the ques-
tionnaire, eleven were reported to occur in the women over
35% of the weeks regardless of the cycle phase. Another eight
symptoms occurred in between 25 and 35 percent of the
weeks irrespective of the phase of the cycle. Only eight symp-
toms occurred during less than 25% of the weeks. So, the
failure to ﬁnd a relationship between most of the symptoms
andadherencemaybeduetothefactthatthesewomenexpe-
rience high rates of symptomology at all times and any given
symptom may not alter their adherence.
Anadditionalproblemwiththisstudywasthesmallsam-
ple of women that were studied. Because of this it was not
possible to examine whether the actual HAART regimen that
was taken by the women could be the cause of the symp-
toms. The women were taking a wide variety of regimens;4 Infectious Diseases in Obstetrics and Gynecology
Table 2: Drug adherence during phases of the menstrual cycle. Chi square = 2.42; P>. 05.
Noncompliance values Week of period N (%) Premenstrual week N (%) Other weeks N (%)
Adherent 77 (88.5) 63 (94.0) 211 (93.4)
Nonadherent 10 (10.3) 4 (6.0) 15 (5.3)
Totals 87 67 226
some were new to HAART; others had been through a vari-
etyofregimens;someswitchedregimensinthemiddleofthe
study; other had non-HIV drugs that they were taking; and
so forth.Alloftheseconsiderations couldhavecausedhigher
or lower numbers of weeks with symptoms. However, with a
sample size of 54 women, it was impossible to have a large
enough “N” to answer this question of any given regimen.
In this study, no relationship between drug adherence
and the phase of the menstrual cycle was found. This was
possibly due to the high levels of adherence that were re-
ported by the women, with their reporting complete adher-
ence in over 90% of the weeks. This was much higher than
theirprimarycarephysicianbelievedtobethecase.However,
the main reason that has been given for lack of adherence has
been “forgetting.” Therefore, it is possible that the weekly re-
minders associated with the phone calls and/or knowing that
someone was checking on their adherence altered their pill
taking behavior.
This pilot study suggested some tendency to have higher
rates of adherence at various diﬀerent phases of the men-
strual cycle. However, the high rates of reported adherence
made it diﬃcult to achieve statistical signiﬁcance—possibly
due to the weekly reminders. Therefore, it is suggested that
the study might be repeated with a larger sample size and
ad i ﬀerent measure of adherence. If pill bottle caps which
record when the bottle is opened are used (as was done in
the Paterson study), or prescription reﬁll data are used to
measure adherence, the patients would not be constantly re-
minded to take their medications. This would be more like
the true situation where there is no one reminding or check-
ing up on the patient. This kind of study might better deter-
mine the eﬀect of the menstrual cycle phase and the symp-
toms on adherence.
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